What is the long-term trend for Nektar Therapeutics's issuance of stock under employee stock plans?

Over 4 years (2021 to 2025), Nektar Therapeutics's issuance of stock under employee stock plans has grown at a -59.8% compound annual growth rate (CAGR), from $33.24M to $866K.

Nektar Therapeutics NKTR Issuance of stock under employee stock plans

Issuance of stock under employee stock plans at other companies

Lumentum Holdings Inc.LITE

$500K+150%

Wintrust FinancialWTFC

$1.91M+4.7%

CloroxCLX

-$2M-300%

ServiceNowNOW

$153M0.0%

ZymeworksZYME

$607K+11.6%

BlockXYZ

$618K-72.9%

Other financials

Income statement

See full

Revenue$10.9M+3.8%

Gross profit$21.8M+2.9%

Operating income-$39.1M+12.3%

Net income-$44.9M+11.7%

EPS (diluted)-$1.82+49.7%

Balance sheet

See full

Cash & equivalents$5.7M-20.0%

Total debt$83.2M-17.1%

Total equity$576.2M+4,094%

Total assets$763.3M+198%

Cash flow

See full

Operating cash flow-$44.3M+9.7%

CapEx$18.0K+800%

Free cash flow-$44.3M+9.7%

Valuation

See full

Market cap$2.19B+1,531%

Profitability

See full

Gross margin100%+31.2pp

Operating margin-242%—

Net margin-284.2%+937pp

FCF margin-366.6%+1,421pp

Returns & leverage

See full

Return on equity-53.6%-22.6pp

Debt / equity0.1×-7.2×

Current ratio10.2×+7.0×

Where this comes from

Reported directly by Nektar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans.

The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nektar Therapeutics's issuance of stock under employee stock plans.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Nektar Therapeutics's issuance of stock under employee stock plans?: Nektar Therapeutics (NKTR) reported issuance of stock under employee stock plans of $4.06M in Q1 2026.
How has Nektar Therapeutics's issuance of stock under employee stock plans changed year-over-year?: Nektar Therapeutics's issuance of stock under employee stock plans increased by 57828.6% year-over-year, from $7K to $4.06M.
What is the long-term trend for Nektar Therapeutics's issuance of stock under employee stock plans?: Over 4 years (2021 to 2025), Nektar Therapeutics's issuance of stock under employee stock plans has grown at a -59.8% compound annual growth rate (CAGR), from $33.24M to $866K.